KRS 311.7736: Reports to cabinet -- Complication or adverse event.

(1) Each abortion-inducing drug as defined in KRS 311.7731 provided to a

pregnant patient by a qualified physician shall be reported to the cabinet as

required by KRS 311.774.

(2) If a qualified physician provides an abortion-inducing drug as defined in KRS

311.7731 to a pregnant woman for the purpose of inducing an abortion, and if

the qualified physician knows that the woman who uses the abortion-inducing

drug for the purpose of inducing an abortion experiences, during or within

fifteen (15) days after the use of the abortion-inducing drug, an adverse event

as defined in KRS 311.7731, the qualified physician shall provide a written

report of the adverse event within three (3) days of the event to the federal

Food and Drug Administration via the MedWatch reporting system, the cabinet,

and the board.

(3) Any physician, qualified physician, associated physician, or other healthcare

provider who diagnoses or knowingly treats a patient, either

contemporaneously to or at any time after a drug-induced abortion, for a

complication or adverse event as defined in KRS 311.7731 related to the

drug-induced abortion shall make a report of the complication or adverse event

to the cabinet on a report form provided by the cabinet. The report shall be

completed and signed by the physician, qualified physician, or other healthcare

provider who diagnosed or treated the complication or adverse event, and

transmitted to the cabinet within three (3) days after the diagnosis or treatment

was provided. Each report shall include at minimum the information required by

KRS 213.101.